Intraocular availability of triamcinolone acetonide after intravitreal injection

Am J Ophthalmol. 2004 Mar;137(3):560-2. doi: 10.1016/j.ajo.2003.08.012.

Abstract

Background: To evaluate the intraocular concentration of triamcinolone acetonide after intravitreal injection.

Methods: The prospective clinical interventional case series study included 17 patients who had received a 20 to 25-mg intravitreal injection of triamcinolone acetonide as treatment for exudative age-related macular degeneration, diffuse diabetic macular edema, or retinal vein occlusions. During a secondary intraocular surgery taking place 4.1 weeks to 25.7 months after the intravitreal injection, aqueous humor samples were obtained. None of the eyes were vitrectomized.

Results: In the aqueous humor samples, triamcinolone acetonide was in low, but measurable, concentrations detected up to 1.5 years after the intravitreal injection. Concentrations found in samples obtained during the first 6 months, or 7 to 12 months, respectively, after the injection ranged between 3.0 microg/l and 436 microg/l, and between 0.0 microg/l and 11.2 microg/l, respectively.

Conclusions: After injection of triamcinolone acetonide, triamcinolone can be present in measurable concentrations up to 1.5 years after the application.

MeSH terms

  • Aqueous Humor / metabolism*
  • Biological Availability
  • Chromatography, High Pressure Liquid
  • Female
  • Gas Chromatography-Mass Spectrometry
  • Glucocorticoids / pharmacokinetics*
  • Humans
  • Injections
  • Macular Degeneration / drug therapy
  • Macular Edema / drug therapy
  • Male
  • Prospective Studies
  • Retinal Vein Occlusion / drug therapy
  • Triamcinolone Acetonide / pharmacokinetics*
  • Vitreous Body / metabolism*

Substances

  • Glucocorticoids
  • Triamcinolone Acetonide